These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28415679)

  • 21. Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
    Mitri ZI; Parmar S; Johnson B; Kolodzie A; Keck JM; Morris M; Guimaraes AR; Beckett BR; Borate U; Lopez CD; Kemmer KA; Alumkal JJ; Beer TM; Corless CL; Mills GB; Gray JW; Bergan RC
    J Transl Med; 2018 Dec; 16(1):358. PubMed ID: 30551737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
    Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
    Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
    Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized genomic analyses for cancer mutation discovery and interpretation.
    Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
    Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.
    Shu Y; Wu X; Tong X; Wang X; Chang Z; Mao Y; Chen X; Sun J; Wang Z; Hong Z; Zhu L; Zhu C; Chen J; Liang Y; Shao H; Shao YW
    Sci Rep; 2017 Apr; 7(1):583. PubMed ID: 28373672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.
    Misyura M; Zhang T; Sukhai MA; Thomas M; Garg S; Kamel-Reid S; Stockley TL
    J Mol Diagn; 2016 Nov; 18(6):842-850. PubMed ID: 27770852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
    Lowder CY; Dhir T; Goetz AB; Thomsett HL; Bender J; Tatarian T; Madhavan S; Petricoin EF; Blais E; Lavu H; Winter JM; Posey J; Brody JR; Pishvaian MJ; Yeo CJ
    Surg Oncol; 2020 Jun; 33():118-125. PubMed ID: 32561076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of circulating cell-free DNA in advanced colorectal cancer.
    Pereira AAL; Morelli MP; Overman M; Kee B; Fogelman D; Vilar E; Shureiqi I; Raghav K; Eng C; Manuel S; Crosby S; Wolff RA; Banks K; Lanman R; Talasaz A; Kopetz S; Morris V
    PLoS One; 2017; 12(8):e0183949. PubMed ID: 28850629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project.
    Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
    JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An institutional review of genomic sequencing in pediatric solid tumors.
    Turco GM; Gupta A; Monteleone P; Kelly KM; Klein RD; Wiltsie L; Barth M
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30324. PubMed ID: 37017066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit for clinical sequencing using cancer panel testing.
    Nishimura S; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Yamamoto Y; Yamauchi M; Sumi T; Kaneda H; Kawaguchi T; Kato M; Tagami M; Oebisu N; Hoshi M; Kimura K; Kubo S; Muguruma K; Takashima T; Ohira M; Yashiro M
    PLoS One; 2021; 16(2):e0247090. PubMed ID: 33635883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center: Identification of Targetable Variants and Experience with Reimbursement.
    Sireci AN; Aggarwal VS; Turk AT; Gindin T; Mansukhani MM; Hsiao SJ
    J Mol Diagn; 2017 Mar; 19(2):277-287. PubMed ID: 28024947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
    Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
    Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.